

# Earnings Release

## 1Q25



São Paulo, Brazil, May 14, 2025 – **Dasa** (B3: DASA3, "Company") today announces its financial results for the first quarter of 2025 (1Q25).

## *Webcast*

May 15, 2025

(in Portuguese with simultaneous translation into English)

2:00 p.m. (Brasília) / 1:00 p.m. (New York) / 6:00 p.m. (London)

Click [\*\*here\*\*](#) to access the link.

Presentation available at: [dasa3.com.br](https://dasa3.com.br)

## Investor Relations

[ir@dasa.com.br](mailto:ir@dasa.com.br)

[dasa3.com.br](https://dasa3.com.br)

# Contents

**MESSAGE FROM THE MANAGEMENT ..... 5**

**1Q25 HIGHLIGHTS ..... 6**

**OPERATIONAL AND FINANCIAL PERFORMANCE ..... 7**

**INVESTMENTS..... 13**

**DEBT ..... 14**

**ESG AGENDA..... 16**

## Considerations on financial and operational information and disclaimers

The financial information presented here was taken from the interim accounting information (“Quarterly Information – ITR”) for the quarter ended March 31, 2025, and prepared in accordance with accounting practices adopted in Brazil and the *International Financial Reporting Standards* (IFRS) issued by the *International Accounting Standards Board* (IASB) and with the standards issued by the Brazilian Securities Commission (CVM) applicable to the preparation of Quarterly Information (ITR).

To facilitate the interpretation of the results and accurately reflect the Company’s internal management structure, the results are presented both on a consolidated basis and divided into two business units: Hospitals and Oncology (BU1) and Diagnostics (BU2). Additionally, the Management makes certain reclassifications between costs and expenses, with no effect on EBITDA and net income. To calculate the financial leverage established in connection with the debentures issued, the Company excludes from general and administrative expenses and, therefore, from EBITDA, expenses with the stock options plan, as determined in the related indentures. Accordingly, the Company uses the word “adjusted” to refer to information with the above alterations, since these reclassifications and adjustments are included in the information presented in the Quarterly Information (ITR). The calculation of EBITDA from net income is shown on page 16. Additionally, the complete information presented here can be found in the interactive spreadsheet available on the Company’s Investor Relations website, by clicking [here](#).

The financial and operational information in this release is subject to rounding off. Consequently, total amounts shown in the tables and graphs may differ from the direct sum of the numbers that precede them. The sum of the financial information of the verticals may not correspond to Dasa’s consolidated financial information, due to the elimination of transactions that occurred between segments, with no effect on EBITDA and net income.

This document may contain forward-looking statements regarding the Company’s business, estimates of operating and financial results and growth prospects, as well as other future events. Forward-looking statements in this document include, but are not limited to, words such as, “anticipate,” “believe,” “estimate,” “expect,” “project,” “plan,” “foresee,” “aim,” and “seek,” as well as all their variations, and other words with similar meanings, which are used to identify possible situations. Said situations involve various factors, risks or uncertainties, known or unknown, which could result in material differences between current data and any projections contained herein, and do not represent any guarantee regarding the Company’s future performance.

All statements in this document are based on information and data available on the date they were made. The Company does not undertake to review or update them in any way with the emergence of new information or future events. The reader/investor is solely and exclusively responsible for any investment decision, trade or action taken based on information contained herein. The reader/investor should not consider only the information herein to make decisions concerning the trading of securities issued by the Company. For more detailed information, please refer to our Financial Statements, Reference Form and other relevant information on our Investor Relations website <https://www.dasa3.com.br/>.

This document does not constitute an offer to sell or a solicitation to buy any security.

## Message from the Management

We begin the year 2025 by continuing the transformation process of Dasa, focusing on making the company more solid, efficient, and profitable, while maintaining our renowned medical and patient care standards as a non-negotiable foundation. We have made progress on the operational, strategic, and financial fronts, guided by careful capital allocation, operational efficiency, excellence in care, and commitment to long-term value creation.

On the strategic front, we took important steps towards the completion of the Joint Venture Agreement with Amil. In 1Q25, we focused our efforts on concluding the internal steps required to close the transaction, including the segregation of Ímpar's assets, the structuring of the debt associated with the new company, corporate reorganizations, and the operational structure of the joint venture. This meticulous effort culminated in the formal closing of the operation on April 1, 2025, marking the beginning of one of the largest independent hospital groups in Brazil, with expanded capacity, operational scale and shared governance between Dasa and Amil.

On the operational front, we continued the execution of the operational excellence program started at the end of 2023, with a focus on productivity, standardization, and control. Among the advances in 1Q25, the highlights are the continued reduction of administrative expenses, the optimization of the operation of diagnostics and hospitals, and the improvement in clinical-operational protocols. These efforts sustained the positive trend of EBITDA margin expansion and contributed to the maintenance of high NPS scores, reflecting the balance between operational efficiency and quality of care.

On the financial front, we had the best net result in a first quarter since 2022 and delivered a consolidated EBITDA of R\$708 million, representing an increase of 11% vs. 1Q24, with margin expansion, even in the face of a very challenging external environment.

We have continued to make solid progress in operating cash generation, sustaining the trend of reducing financial leverage that has been observed since the first quarter of 2024. The permanent focus on working capital management and the judicious allocation of investments, along with the growth in results, has been essential to sustain this movement.

We are, therefore, following the process of evolution and construction of a more focused, efficient Company prepared for the challenges of the sector, with financial discipline, operational excellence and long-term vision.

In this time of intense transformation, we thank all our employees, stakeholders, investors and the market as a whole for their dedication, trust and partnership.

**THE BOARD.**

## 1Q25 Highlights

(R\$ million)	1Q24	1Q25	Δ
Consolidated gross revenue	<b>4,069</b>	<b>4,213</b>	<b>4%</b>
Gross revenue BU1	2,103	2,134	2%
Gross revenue BU2	1,967	2,079	6%
Adjusted gross profit	<b>1,130</b>	<b>1,217</b>	<b>8%</b>
Adjusted gross margin	30.3%	31.8%	1.5 p.p.
Adjusted expenses	<b>(492)</b>	<b>(508)</b>	<b>3%</b>
% Net revenue	-13.2%	-13.3%	-0.1 p.p.
EBITDA	<b>639</b>	<b>708</b>	<b>11%</b>
Operating cash generation <sup>1</sup>	<b>(218)</b>	<b>(43)</b>	<b>175</b>
Investments	<b>53</b>	<b>69</b>	<b>15</b>

- **Operating cash generation<sup>1</sup> in 1Q25 was R\$175 million better than in 1Q24.**
- **Net financial debt** after acquisitions payable and advance on receivables to EBITDA 0.97x **lower** than in 1Q24 (0.08x higher than in 4Q24, mainly due to seasonal and specific factors).
- **Expanding gross revenue**, with growth of 6% in Diagnostics and 15% in Oncology with a highlight of a 1.7 p.p. increase in the occupancy rate in Hospitals.
- **4% reduction in adjusted expenses**, with **drop of 0.9 p.p. as % of net revenue**, excluding out-of-period tax credits reported in 1Q24.
- **Growth of 11% in EBITDA**, driven by **expansion of revenue** and **results from the operational excellence program**.
- **Maintenance of the investment level**, with a focus on the monetization of assets resulting from relevant investments made in previous years.

<sup>1</sup> Taken from the Statement of Cash Flows, in the Financial Statements, and calculated as follows: a) cash flow generated (used) by operating activities plus b) interest paid on loans, financing and debentures less c) payment of lease principal.

## Operational and Financial Performance

### Gross and net operating revenue

(R\$ million)	1Q24	1Q25	Δ
<b>Consolidated gross revenue</b>	<b>4,069</b>	<b>4,213</b>	<b>4%</b>
BU1	2,103	2,134	2%
BU2	1,967	2,079	6%
(-) Taxes and deductions	(341)	(387)	13%
<b>Consolidated net revenue</b>	<b>3,728</b>	<b>3,826</b>	<b>3%</b>
BU1	1,924	1,905	-1%
BU2	1,804	1,921	6%

The Company recorded consolidated gross revenue of R\$4.2 billion in 1Q25, representing a growth of 4% compared to 1Q24. The performance was positive in both business units: Hospitals and Oncology (BU1) increased 2%, while Diagnostics (BU2) recorded an increase of 6%. Consolidated net revenue totaled R\$3.8 billion in 1Q25, a growth of 3% compared to the same period last year.

## Hospitals and Oncology – BU1


(R\$ million)	1Q24	1Q25	Δ
<b>Net revenue BU1</b>	<b>1,924</b>	<b>1,905</b>	<b>-1%</b>
Hospitals	1,583	1,522	-4%
Oncology	342	383	12%

Gross revenue from Hospitals and Oncology reached R\$2.1 billion in 1Q25, 2% higher than in 1Q24, mainly due to the interruption of certain less profitable operations, which initially reduce revenue growth, but allow for better results over time. This positioning led to a 10% lower volume of patients-day in 1Q25 compared to 1Q24, which was offset by a 12% increase in the average ticket, mainly resulting from a better mix of procedures and growth in Oncology.


This decline is attributed to an increased level of provisions for disallowances, which had an estimated impact of R\$34 million. This change resulted from the statistical provisioning model adopted starting in 4Q23.

### Operating indicators – BU1 (Hospitals and Oncology)


**Total beds and active beds**  
(# monthly average)




**Occupancy rate (%)**



**Patients-day (# average of patients)**



**Average ticket<sup>1</sup> (R\$)**




<sup>1</sup>BU1's average ticket = BU1's gross revenue / number of patients-day.

## Diagnostics – BU2

(R\$ million)	1Q24	1Q25	Δ
<b>Net revenue BU2</b>	<b>1,804</b>	<b>1,921</b>	<b>6%</b>
BU2 - National	1,731	1,797	4%
BU2 - International	73	124	69%

BU2's net revenue in 1Q25 was R\$1.9 billion, 6% higher than in 1Q24, a similar increase to that of gross revenue, mainly due to the 5% growth in the volume of exams. Revenue growth in this quarter was reduced by the sale of Dasa Empresas in 4Q24, the closure of 35 less profitable units, and the deprioritization of home care services, with a combined impact estimated at R\$42 million. Excluding these effects, BU2's net revenue growth would have been 9%.

### Operating indicators – BU2 (Diagnostics)



<sup>1</sup>BU2's average ticket = BU2's gross revenue / number of exams.

## Operating costs, gross profit and gross margin

(R\$ million)	1Q24	1Q25	Δ
<b>Adjusted costs by BU</b>	<b>(2,598)</b>	<b>(2,610)</b>	<b>0%</b>
BU1	(1,444)	(1,417)	-2%
BU2	(1,154)	(1,193)	3%
<b>Adjusted costs by category</b>	<b>(2,598)</b>	<b>(2,610)</b>	<b>0%</b>
Personnel	(778)	(741)	-5%
Material	(872)	(897)	3%
General services and utilities	(947)	(972)	3%
<b>Adjusted gross profit</b>	<b>1,130</b>	<b>1,217</b>	<b>8%</b>
<i>Adjusted gross margin</i>	<i>30.3%</i>	<i>31.8%</i>	<i>1.5 p.p.</i>
<b>BU1</b>	<b>480</b>	<b>489</b>	<b>2%</b>
<i>Adjusted gross margin BU1</i>	<i>25.0%</i>	<i>25.6%</i>	<i>0.7 p.p.</i>
<b>BU2</b>	<b>650</b>	<b>728</b>	<b>12%</b>
<i>Adjusted gross margin BU2</i>	<i>36.0%</i>	<i>37.9%</i>	<i>1.8 p.p.</i>

Adjusted operating costs totaled R\$2.6 billion in 1Q25, in line with the amounts reported in 1Q24. This growth was lower than the 4% rise in gross revenue, resulting in a R\$86 million increase in consolidated adjusted gross profit. Adjusted gross margin in 1Q25 was 31.8%, up 1.5 p.p. from 1Q24.


### Hospitals and Oncology – BU1

Adjusted operating costs from Hospitals and Oncology totaled R\$1.4 billion in 1Q25, down 2% from 1Q24. This evolution results from a 10% lower volume of patients-day and an 11% reduction in active beds, partially offset by (i) higher costs arising from the new nursing legislation and inflation over the past twelve months, (ii) higher costs of materials and medications, mainly due to the growing participation of the Oncology segment, and (iii) out-of-period credits related to social security funds amounting to R\$12 million accounted for in 1Q24, as reported at the time.

As a result, the adjusted gross profit for Hospitals and Oncology totaled R\$489 million in 1Q25, representing a 2% growth compared to 1Q24, leading to an expansion of 0.7 p.p. in the adjusted gross margin.

Normalizing the period based on (i) the effect of the higher level of provision for disallowance in 1Q25, estimated at R\$34 million, and (ii) the benefit from out-of-period credits of R\$12 million in 1Q24, as mentioned above, the adjusted gross profit of Hospitals and Oncology in 1Q24 would have been R\$434 million, with a gross adjusted margin of 23%. Therefore, the gross adjusted profit of R\$489 million realized in 1Q25 represents an increase of 13% compared to 1Q24 calculated above, and a gain of 2.7 p.p. in adjusted gross margin.

**Adjusted gross margin - Hospitals and Oncology**  
(% of BU1's net revenue)




**Diagnostics – BU2**

Adjusted operating costs of the Diagnostics business unit were R\$1.2 billion in 1Q25, 3% higher than in 1Q24, lower than the growth in revenue, which allowed adjusted gross profit to increase 12% to R\$728 million. With this, adjusted gross margin in 1Q25 reached 37.9%, up 1.8 p.p. from 1Q24.

This positive evolution of BU2's adjusted gross profit was driven by an increase in the volume of operations and the benefits from the operational excellence program, partially offset by the inflation accumulated in the period.

**Adjusted gross margin - Diagnostics**  
(% of BU2's net revenue)



## General & administrative expenses/ Other income and expenses

(R\$ million)	1Q24	1Q25	Δ
General and administrative expenses Adjusted	(521)	(537)	3%
Other operating income and expenses	30	29	-3%
<b>Adjusted expenses</b>	<b>(492)</b>	<b>(508)</b>	<b>3%</b>
<i>% Net revenue</i>	<i>-13.2%</i>	<i>-13.3%</i>	<i>-0.1 p.p.</i>

Consolidated adjusted expenses totaled R\$508 million in 1Q25, up 3% from 1Q24. Excluding the out-of-period tax credits that positively impacted 1Q24 by R\$37 million, as reported at the time, adjusted expenses decreased by 4% compared to the previous year, reflecting the results of the operational excellence program, which focuses on reviewing management processes and organizational structure, prioritizing activities and renegotiating service contracts.

Considering this effect, adjusted expenses as a percentage of net revenue fell by 0.9 p.p. in comparison with the same period last year.

## EBITDA, financial result and net result

(R\$ million)	1Q24	1Q25	Δ
<b>Net result</b>	<b>(176)</b>	<b>(111)</b>	<b>-37%</b>
(+) Income tax and social contribution	(5)	7	-226%
(+) Net financial result	485	475	-2%
(+) Depreciation and amortization	335	337	1%
<b>EBITDA</b>	<b>639</b>	<b>708</b>	<b>11%</b>
<i>EBITDA margin</i>	<i>17.1%</i>	<i>18.5%</i>	<i>1.4 p.p.</i>

The Company's consolidated EBITDA was R\$708 million in 1Q25, an increase of 11% vs. 1Q24, due to (i) the results of actions linked to the operational excellence program, and (ii) the expansion of the volume of operations, particularly in Oncology and Diagnostics, resulting in a 1.4 p.p. increase in the EBITDA margin.

Normalizing the 1Q24 based on the effect of the higher level of provision for disallowances in BU1 in 1Q25, with an estimated impact of R\$34 million, EBITDA in 1Q24 would have been R\$605 million, which would have resulted in an increase of 17% in the EBITDA of 2025. As a result, the EBITDA margin would have grown 2.1 p.p., from 16.4% in 1Q24 to 18.5% in 1Q25.

Net financial result in 1Q25 was an expense of R\$475 million, 2% lower than the expense of R\$485 million in 1Q24, with the benefit of lower net debt in 1Q25 being offset by the higher interest rates in 1Q25 compared to 1Q24.

Net result in 1Q25 was a loss of R\$111 million, which is R\$66 million better than the R\$176 million loss reported in 1Q24. This improvement is attributed to an 11% increase in EBITDA, a better financial result, and stable depreciation and amortization expenses, as a result of changes in the investment allocation pattern over the past 12 months.




# Investments

(R\$ million)	1Q24	1Q25	Δ
<b>Total investments</b>	<b>53</b>	<b>69</b>	<b>29%</b>
<i>% Gross revenue</i>	<i>1.3%</i>	<i>1.6%</i>	<i>0.3 p.p.</i>
<b>Investments by category</b>	<b>53</b>	<b>69</b>	<b>29%</b>
Maintenance and Expansion	36	50	37%
Technology	16	19	15%
<b>Investments by BU</b>	<b>53</b>	<b>69</b>	<b>29%</b>
BU1	23	24	4%
BU2	14	28	100%
Corporate	17	17	3%

Consolidated investments totaled R\$69 million in 1Q25, R\$15 million higher than the R\$53 million recorded in 1Q24, mainly in maintenance and expansion at BU2

In line with the operational excellence program, the Company maintains its focus on optimizing investments, prioritizing projects with higher returns in the short term, in addition to maintaining existing assets and sustaining technology services essential to operations.

**Investments**  
(R\$ million)





## Indebtedness

### Financial cash and debt position

(R\$ million)	1Q24	2Q24	3Q24	4Q24	1Q25
Gross financial debt	11,738	11,378	11,584	10,722	12,906
(-) Cash and cash equivalents / securities	2,115	2,987	2,820	1,895	3,576
<b>Net financial debt</b>	<b>9,622</b>	<b>8,391</b>	<b>8,765</b>	<b>8,827</b>	<b>9,331</b>
Acquisitions payable	1,236	1,253	1,135	1,068	1,049
Cash from financial advance on receivables	612	430	145	157	171
<b>Net financial debt after acquisitions payable and advances on receivables</b>	<b>11,470</b>	<b>10,075</b>	<b>10,044</b>	<b>10,051</b>	<b>10,551</b>
Net financial debt after acquisitions payable and advances on receivables / EBITDA	<b>5.14 x</b>	<b>4.24 x</b>	<b>4.07 x</b>	<b>4.08 x</b>	<b>4.17 x</b>

The Company ended 1Q25 with a net financial debt after acquisitions payable and advances on receivables of R\$10.6 billion, representing 4.17x the EBITDA of the last 12 months, a reduction of 0.97x (19%) compared to 1Q24.


With respect to 4Q24 the net financial debt ratio after acquisitions payable and advances on receivables / EBITDA increased 0.08x (2%), mainly due to the typical seasonality observed between the first and fourth quarters and a one-time increase in the average collection period, for which the Company's focus contributed to the closing the Joint Venture Agreement in the last weeks of March this year.

In 1Q25, gross financial debt was R\$12.9 billion, with an average term of 3.4 years and average cost of CDI + 2.20% p.a. In preparation for the closing of the Joint Venture Agreement with Amil, the Company issued debentures in the amount of R\$3.0 billion and used part of the proceeds for the early redemption of the 18th issuance of debentures, in the amount of R\$1.0 billion. The remaining balance from the funding was used to redeem the 20th issue of debentures in the amount of R\$1.3 billion on April 8, 2025 and to strengthen the Company's cash position.

At the end of 1Q25, the cash, cash equivalents and marketable securities balance was R\$3.6 billion, representing approximately 1.0x the debts of R\$3.6 billion falling due by the end of 2026.

#### Amortization schedule – Gross Financial Debt

(R\$ million)



## Leverage covenant

(R\$ million)	1Q24	2Q24	3Q24	4Q24	1Q25
<b>Net financial debt</b>	<b>9,622</b>	<b>8,391</b>	<b>8,765</b>	<b>8,827</b>	<b>9,331</b>
Adj. EBITDA covenant LTM	2,293	2,420	2,502	2,485	2,559
<b>Leverage covenant<sup>1</sup></b>	<b>4.20x</b>	<b>3.47x</b>	<b>3.50x</b>	<b>3.55x</b>	<b>3.65x</b>

Leverage ratio for the purpose of *covenants* ended 1Q25 at 3.65x, stable in relation to 4Q24 and below the limit of 4.0x set in the debt transaction indentures.

## Ratings

	Agency	Rating	Review
Dasa – Corporate	Fitch Ratings	AA(bra)	04/01/2025
10th Debenture	Fitch Ratings	AA(bra)	04/01/2025
11th Debenture	Fitch Ratings	AA(bra)	04/01/2025
14th Debenture	Fitch Ratings	AA(bra)	04/01/2025
15th Debenture	Fitch Ratings	AA(bra)	04/01/2025
17th Debenture	Fitch Ratings	AA(bra)	04/01/2025
20th Debenture	Fitch Ratings	AA(bra)	04/01/2025
21st Debenture	Fitch Ratings	AA(bra)	04/01/2025
2nd Debenture – Ímpar	Fitch Ratings	AA-(bra)	05/07/2025

[Click here](#) to read the Company's rating reports.

<sup>1</sup> Net Debt/EBITDA (calculated as per the indentures)

 **ESG Agenda****Governance****Approval of Accounts**

On March 26, 2025, the Board of Directors unanimously approved without reservations the management report, the accounts of the directors, and the Company's financial statements, accompanied by the independent auditors' report and the opinion of the Statutory Audit Committee, related to the fiscal year ended December 31, 2024, as well as the call for the Annual Shareholders' Meeting of Dasa held on April 30, 2025 to deliberate on the above topics. Also on March 26, 2025, the activity report of the Statutory Audit Committee for the year 2024 was released.

**Subscription Warrant**

Also on March 26, 2025, and in continuation of the resolutions approved at the Board of Directors' meetings held on April 4 and 18, 2023, within the scope of the public offering of primary distribution of common shares issued by the Company, carried out in Brazil, under the automatic registration procedure before the Securities and Exchange Commission, pursuant to CVM Resolution No. 160, of July 13, 2022, as amended, with efforts to place the shares internationally, the Board of Directors of Dasa approved the re-ratification of the quantity of subscription warrants from 19,685,740 to 19,685,738 and approved the opening of the period for the exercise of the subscription warrants, which began on April 1, 2025 (inclusive) and ended on April 15, 2025 (inclusive), at a price of R\$3.17171460565751 per subscription warrant, upon payment in cash and in local currency, according to the period and procedures for exercise provided for in the respective Board meeting minutes and Notice to Shareholders published on March 31, 2025. On May 7, 2025, the Company announced the determination of the number of subscription warrants exercised and the corresponding capital increase of Dasa.

**Annual and Extraordinary Shareholders' Meeting**

On April 30, 2025, the Annual and Extraordinary Shareholders' Meeting of the Company was held, which resolved on the approval of the accounts and reports related to the fiscal year ended December 31, 2024, and also on (i) the determination of the number of members of the Board of Directors; (ii) the election of the members of Dasa's Board; (iii) the annual overall compensation of the Company's Members of Management for the period from January 1 to December 31, 2025; and (iv) at the Extraordinary Shareholders' Meeting on (d) the re-ratification of the annual overall compensation of the directors approved for the fiscal year ended December 31, 2024.

**Dasa and Amil Joint Venture Agreement (Continued) and Changes in the Statutory Board**

At the Board of Directors' meeting held on March 31, 2025, it was unanimously approved by the directors: (i) the ratification of the fulfillment of the net indebtedness assumption of Ímpar, a wholly-owned subsidiary of Dasa, as provided in the Joint Venture Agreement with Amil, in the amount of R\$ 3.5 billion; (ii) the verification and confirmation of the implementation of the conditions precedent subject to the waivers granted between the parties, as agreed in the Joint Venture Agreement (except for the condition precedent linked to the implementation of the spin-off of Ímpar and incorporation by Dasa and Dasa Real, as applicable); (iii) in view of the deliberations of items (i) and (ii) above, the verification of the effectiveness and legal effects of the aforementioned spin-off and incorporation operation, so that Dasa and Dasa RE incorporated the

spun-off assets of Ímpar destined for Dasa and Dasa RE, according to the terms of the Protocol and Justification of the operation disclosed and approved by the competent bodies of Dasa and Dasa RE.

In the same meeting, the Board of Directors of Dasa, subject to the closing of the Joint Venture Agreement scheduled for April 1, 2025, and, furthermore, considering the new governance of Ímpar and the restructuring of the composition of the statutory executive boards of Dasa and Ímpar expected as a result of the implementation of the Joint Venture, approved the following topics:

(i) CEO succession plan

Succession plan for Mr. Lício Cintra, with the election of Mr. Rafael Lucchesi, as of July 1, 2025, remaining, during the transition period, Mr. Lício Cintra as Chief Executive Officer of Dasa and Ímpar, and it is certain that as of July 1, 2025, Mr. Lício Cintra will leave the position as Chief Executive Officer on June 30, 2025 (remaining only as Chief Executive Officer of Ímpar) and Mr. Rafael Lucchesi will take office as of July 1, 2025.

(ii) Resignation of Officers

Dasa's Board members acknowledged the resignation of Mrs. Maria José Campos (Majo Campos) and Messrs. Rogério Reis and Carlos Prebelli from their positions as Directors without Specific Designation.

(iii) Election of new Officers

In continuity with the deliberations, the election of Mr. Rafael Bossolani as Chief Financial and Investor Relations Officer was approved, replacing Mr. André Covre who assumed the new position as Corporate Strategy Officer, as well as the election of Mr. Roberto Cury to the position of Service Units and Customer Service Center Officer and Mrs. Anaterrea Barros, to the position of Technology Officer.

(iv) Consolidation of the Statutory Board

Finally, considering the deliberations above, it was approved, from the closing of the Joint Venture Agreement, the consolidation of the Statutory Board of Dasa with the following composition and unified mandate: (a) Chief Executive Officer: Lício Tavares Ângelo Cintra; (b) Chief Financial and Investor Relations Officer: Rafael Bossolani; (c) Chief Executive Officer of the Diagnostics Unit (Chief Executive Officer of the Company from July 1, 2025): Rafael Lucchesi; (d) Corporate Strategy Officer: André Covre; (e) Production Director: Linaldo Vilar Junior; (f) Medical and Operations Officer: Leonardo Modesti Vedolin; (g) Product, Marketing, Analytics and Customer Experience Officer: Helisson Brígido Andrade Lemos; (h) People, Management and Culture Executive Officer: Fábio Sampaio de Lacerda; (i) Service Units and Customer Service Center Officer: Roberto Caldeira Cury; and (j) Technology Officer: Anaterrea Barros de Oliveira.

## **Events after the reporting period**

### **Closing of the Joint Venture Agreement**

In continuation of the Material Facts of June 14, 2024 and February 4, 2025, and the Notices to the Market of December 26, 2024 and January 14, 2025, on April 1, 2025, the closing of the Joint Venture Agreement between Dasa and Amil was announced, making Ímpar, Dasa's hospitals and oncology company, a joint venture (jointly controlled enterprise) with equal 50% voting capital shares between Amil and Dasa and shared control. The Material Fact of Dasa released on April 1, 2025 addressed the new structure of Rede Américas, the composition of the indebtedness of

Ímpar and Dasa upon the closing of the transaction, the new governance and management structure of the companies, as well as the agreements signed and provided for in the Joint Venture Agreement and the accounting effects resulting from the joint control over Ímpar by Dasa and Amil.

## **Social**

### **Diversity, Equity, and Inclusion**

In early 2025, the Diversity Strategy Planning for the year was carried out, reinforcing the company's focus on Gender and Racial Equity, while working on the inclusion of other socially marginalized groups, such as People with Disabilities, LGBTI+ People and Generational Diversity.

The new model of Diversity Meeting is held with the participation of all minority groups and allied people, where the topics are put on the agenda and the appropriate priorities are defined, as we understand that the creation of an inclusive society must be experienced and practiced by all people. Thus, when setting a priority, we understand the process and the impact on the entire company.

We continue with awareness and education actions on topics related to diversity, inclusion, respect and human rights, through internal campaigns, meetings, live streams and training. Topics covered in the period include:

- The company's Diversity Governance and the Diversity Committees of our units;
- Priority projects for the 2025 Diversity Strategy;
- Visibility of Transgender People, bringing information and positive testimonies of inclusion of our people;
- International Day of Women and Girls in Science, addressing gender equality in the fields of Science and Health;
- Women's Month, addressing the rights conquered by women and the challenges that persist.

New training trails have been added to our Corporate University, one of which focuses on the development of inclusive leadership. We achieved more than 30 new lessons produced especially for the development of our people, using *Microlearning* principles, through light and interactive content bites, while maintaining appropriate depth. So far, we have registered more than 4,000 completions in the available courses, with steady monthly evolution.

The filed documents are available on the Company's Investors Relations website ([click here](#)).

